|Source||Chimeric/humanized hybrid (mouse/human)|
|Chemical and physical data|
|Molar mass||148.3 kDa|
Depatuxizumab mafodotin (INN) is a chimeric and humanized monoclonal antibody designed for the treatment of cancer.
This drug was developed by AbbVie.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin, American Medical Association.
- World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).